Novel activity of acriflavine against colorectal cancer tumor cells
2011 (English)In: Cancer Science, ISSN 1347-9032, E-ISSN 1349-7006, Vol. 102, no 12, 2206-2213 p.Article in journal (Refereed) Published
A high-throughput screen of the cytotoxic activity of 2000 molecules from a commercial library in three human colon cancer cell lines and two normal cell types identified the acridine acriflavin to be a colorectal cancer (CRC) active drug. Acriflavine was active in cell spheroids, indicating good drug penetration and activity against hypoxic cells. In a validation step based on primary cultures of patient tumor cells, acriflavine was found to be more active against CRC than ovarian cancer and chronic lymphocytic leukemia. This contrasted to the activity pattern of the CRC active standard drugs 5-fluorouracil, irinotecan and oxaliplatin. Mechanistic studies indicated acriflavine to be a dual topoisomerase I and II inhibitor. In conclusion, the strategy used seems promising for identification of new diagnosis-specific cancer drugs.
Place, publisher, year, edition, pages
2011. Vol. 102, no 12, 2206-2213 p.
Acriflavine, colorectal cancer, topoisomerase, drug screening
Pharmacology and Toxicology
Research subject Medicine
IdentifiersURN: urn:nbn:se:uu:diva-130189DOI: 10.1111/j.1349-7006.2011.02097.xISI: 000297202800013OAI: oai:DiVA.org:uu-130189DiVA: diva2:347950
De två första författarna delar förstaförfattarskapet2010-09-032010-09-032013-03-26Bibliographically approved